AU2003251734A1 - Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve - Google Patents

Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve

Info

Publication number
AU2003251734A1
AU2003251734A1 AU2003251734A AU2003251734A AU2003251734A1 AU 2003251734 A1 AU2003251734 A1 AU 2003251734A1 AU 2003251734 A AU2003251734 A AU 2003251734A AU 2003251734 A AU2003251734 A AU 2003251734A AU 2003251734 A1 AU2003251734 A1 AU 2003251734A1
Authority
AU
Australia
Prior art keywords
mmdl
nicergoline
mdl
retina
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251734A
Inventor
Angelo Battaglia
Laura Calza'
Nicola Carfagna
Luciana Giardino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of AU2003251734A1 publication Critical patent/AU2003251734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003251734A 2002-07-25 2003-07-02 Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve Abandoned AU2003251734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02078034.2 2002-07-25
EP02078034 2002-07-25
PCT/EP2003/050283 WO2004011003A1 (en) 2002-07-25 2003-07-02 Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve

Publications (1)

Publication Number Publication Date
AU2003251734A1 true AU2003251734A1 (en) 2004-02-16

Family

ID=30775842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251734A Abandoned AU2003251734A1 (en) 2002-07-25 2003-07-02 Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve

Country Status (2)

Country Link
AU (1) AU2003251734A1 (en)
WO (1) WO2004011003A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Also Published As

Publication number Publication date
WO2004011003A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
AU2003258305A1 (en) Combination therapy for treatment of fibrotic disorders
AU2003300791A1 (en) Combination therapy for the treatment of pain
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
AU2604301A (en) Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
AU2002255248A1 (en) Diagnosis, treatment and research of mental disorders
PL378108A1 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL173351A0 (en) Therapy of ocular disorders
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU6910600A (en) Methods for the treatment of mental disorders
AU2003263628A1 (en) Medical treatment system for stimulating spots on the body suitable for acupuncture
AU2003209150A1 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
AU2002241343A1 (en) Decoy compositions for treating and preventing brain diseases and disorders
AU2003904328A0 (en) Diagnosis and treatment of neurodegenerative disorders
AU2003291253A1 (en) Scleral implants for treatment of eye disorders
AU2003278559A1 (en) Herbal medicine containing cyclodextrins for the treatment of ear disorders
AU7106300A (en) Treatment of skin disorders
AU2003301267A1 (en) Photodynamic therapy for ocular neovascularization
AU2003251734A1 (en) Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders